Inspire Medical Systems Inc

US

Health Care

225.22 ₽

Current price

Hold
225.22 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    156 / 663

  • Position in country

    3122 / 14179

  • Return on Assets, %

    -3.9

    -11.9

  • Net income margin, %

    7.6

    -12.5

  • EBITDA margin, %

    5.2

    -2.5

  • Debt to Equity, %

    0

    15

  • Intangible assets and goodwill, %

    0

    3.9

  • Revenue CAGR 3Y, %

    75.6

    12.6

  • Total Equity change 1Y, %

    15.4

    0

  • Revenue Y, % chg

    53.1

    4.6

  • P/BV

    11.9

    1.7

  • P/S

    11.2

    3.7

  • EV/S

    10.5

    3.2

  • EV/EBITDA

    -147.2

    -0.2

  • Average Analyst recommendation

    Hold

    Hold

  • Average upside forecasts, %

    14.3

    66.5

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Dexcom Inc

    00%

  • Inspire Medical Systems Inc

    00%

  • Boston Scientific Corp

    00%

  • Intuitive Surgical Inc

    00%

  • Stryker Corp

    00%

  • Edwards Lifesciences Corp

    00%

  • IDEXX Laboratories Inc

    00%

  • Abbott Laboratories

    00%

  • GE Healthcare Technologies Inc

    00%

  • Becton Dickinson and Co

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    United States of America

  • Sector

    Health Care

  • Industry group

    Health Care Equipment & Services

  • Industry

    Health Care Equipment & Supplies

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    7021

  • Ticker

    INSP.K

  • ISIN

    US4577301090

  • IPO date

    2018-05-03

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-09

  • Date fact. publication of reports

    2023-12-31

Company Description

Inspire Medical Systems, Inc. is a medical technology company. The Company is focused on the development and commercialization of invasive solutions for patients with obstructive sleep apnea (OSA). The Company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The therapy is indicated for patients with moderate to severe OSA who do not have significant central sleep apnea and do not have a complete concentric collapse of the airway at the soft palate level. The Company sells its system to the hospitals and ambulatory surgery centers (ASCs) in the United States and in select countries in Europe through a direct sales organization.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: